Acorda Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
March 04, 2021 at 04:03 pm EST
Share
Acorda Therapeutics, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced total revenue was USD 38.160 million compared to USD 50.497 million a year ago. Operating loss was USD 78.395 million compared to operating Income of USD 14.486 million a year ago. Net loss was USD 83.048 million compared to net income of USD 65.660 million a year ago. Basic loss per share from continuing operations was USD 9.82 compared to basic earnings per share from continuing operations of USD 8.27 a year ago. Diluted loss per share from continuing operations was USD 9.82 compared to diluted earnings per share from continuing operations of USD 8.26 a year ago. For the full year, total revenue was USD 152.967 million compared to USD 192.408 million a year ago. Operating loss was USD 78.076 million compared to USD 311.632 million a year ago. Net loss was USD 99.594 million compared to USD 272.966 million a year ago. Basic loss per share from continuing operations was USD 12.32 compared to USD 34.43 a year ago.
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.